StoxBiocon vs Concord Biotech: share price & financials comparison
NSE: BIOCON vs CONCORDBIO · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Biocon vs Concord Biotech at a glance
Biocon (BIOCON) has a market capitalisation of ₹59,326 Cr, against ₹6,214 Cr for Concord Biotech (CONCORDBIO). Over the past year Biocon has returned -4.3%, compared with -18.3% for Concord Biotech. On valuation, Concord Biotech trades at a lower P/E of 22.0 versus 131.2. Concord Biotech earns a higher return on equity (13.6% vs 1.3%). Biocon comes out ahead on size and momentum. Concord Biotech comes out ahead on valuation, profitability, growth and technicals. Across the scored metrics below, Biocon leads on 7 and Concord Biotech on 8. On StoxGud's 10-point checklist, Biocon scores 2/10 and Concord Biotech scores 6/10.
| Metric | Biocon | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹59,326 Cr | ₹6,214 Cr |
| Revenue (latest FY) | ₹16,927 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹386 Cr | ₹261 Cr |
| Valuation | ||
| P/E | 131.2 | 22.0 |
| P/B | 1.70 | 2.99 |
| Dividend yield | 0.15% | 1.80% |
| Profitability | ||
| Return on equity | 1.3% | 13.6% |
| Net profit margin | 2.6% | 24.1% |
| Operating margin | 20.3% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | +2.2% | +25.1% |
| Net profit growth (YoY) | -51.1% | +11.1% |
| Revenue CAGR (multi-year) | +19.0% | +1.8% |
| Financial health | ||
| Debt to equity | 0.43 | 0.00 |
| Momentum | ||
| 1-month return | +3.7% | -13.3% |
| 1-year return | -4.3% | -18.3% |
| 3-year CAGR | +17.0% | -3.0% |
| 5-year CAGR | +0.1% | — |
| 10-year CAGR | +9.8% | — |
| Distance from 52W high | -17.4% | -25.2% |
| Technicals | ||
| RSI (14) | 76 | 47 |
| Price vs 200-day avg | -6.7% | -6.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Biocon | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 2/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Biocon or Concord Biotech?
Biocon has a market cap of ₹59,326 Cr and Concord Biotech has a market cap of ₹6,214 Cr as of 13 Nov 2026.
Which has a lower P/E, Biocon or Concord Biotech?
Concord Biotech has the lower P/E: Biocon trades at 131.2 and Concord Biotech at 22.0.
Which gave better returns in the last year, Biocon or Concord Biotech?
Biocon did better: Biocon returned -4.3% and Concord Biotech returned -18.3% over one year.
What is the difference between Biocon and Concord Biotech?
Both are NSE-listed companies in Healthcare. Biocon is about 9.5 times the size of Concord Biotech by market cap. In the latest financial year Biocon reported revenue of ₹16,927 Cr and Concord Biotech ₹1,055 Cr. Operating margin is 20.3% for Biocon and 34.5% for Concord Biotech. Debt to equity is 0.43 for Biocon and 0.00 for Concord Biotech.
Which is better, Biocon or Concord Biotech?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Biocon leads on 7 and Concord Biotech on 8. Biocon is ahead on size and momentum. Concord Biotech is ahead on valuation, profitability, growth and technicals. On StoxGud's rules-based checklist Biocon scores 2/10 and Concord Biotech scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.